ERBB2 and neoplasm: The PI3K/Akt/NF-κB pathway has shown positive outcomes in BCSC-based therapies, especially for HER-2 positive cancers, with researchers reporting reduced tumor growth and metastasis, which result in improved patient outcomes [156].